

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 July 2024 (11.07.2024)



(10) International Publication Number
WO 2024/148329 A1

(51) International Patent Classification:

A61K 31/713 (2006.01) C12N 15/113 (2010.01)
A61K 47/54 (2017.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/010584

(22) International Filing Date:

05 January 2024 (05.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/478,795 06 January 2023 (06.01.2023) US
63/612,901 20 December 2023 (20.12.2023) US

(71) Applicant: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 East Colorado Boulevard, Suite 700, Pasadena, CA 91105 (US).

(72) Inventors: **MAJEWSKI, Mark**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **GLEBOCKA, Agnieszka**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **PEI, Tao**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **BENSON, Jonathan**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **XU, Zhao**; Arrowhead Pharmaceuticals, Inc., 10102 Hoyt Park Drive, San Diego, CA 92131 (US).

(74) Agent: **VANDERVELDE, Paul**; 10102 Hoyt Park Drive, San Diego, CA 92131 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE

(57) Abstract: Disclosed herein are compounds comprising lipid PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents or antisense oligonucleotides, to certain tissues (e.g., adipose tissue) or cell types (e.g., adipocytes) *in vivo*. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the adipocytes *in vivo* to facilitate the inhibition of gene expression in those cells.

WO 2024/148329 A1